Real-World Experience of Concomitant Isavuconazole and Vincristine Administration
Three pediatric oncology patients received isavuconazole concurrently with vincristine across 15 days to approximately 23 months, spanning 32 vincristine doses. No severe adverse effect including neurotoxicity or paralytic ileus was attributed to the combination.
Authors
- James T. Gaensbauer (ORCID: https://orcid.org/0000-0002-0732-4150)
- Theresa Madigan (ORCID: https://orcid.org/0000-0003-3597-3665)
- Anand Srinivasan (ORCID: https://orcid.org/0000-0002-4983-5039)
- Paul J. Galardy (ORCID: https://orcid.org/0000-0002-0322-8882)
- Madeleine B. O'Keefe (ORCID: https://orcid.org/0009-0008-5397-2483)
- Alexis K. Kuhn (ORCID: https://orcid.org/0000-0001-5256-5001)
- Mira A. Kohorst (ORCID: https://orcid.org/0000-0002-1865-7444)
- Catherine Martin (ORCID: https://orcid.org/0000-0003-2961-4666)
- Laura Dinnes (ORCID: https://orcid.org/0000-0001-7630-5642)
- Mohamad Shieb (ORCID: https://orcid.org/0009-0009-7008-3685)
- Abbie L. Blunier (ORCID: https://orcid.org/0000-0002-3809-6226)
- Ashley Walter
- John Guggenburger
Institutions
- Mayo Clinic (US)
Publication Details
- Journal
- Journal of the Pediatric Infectious Diseases Society
- Published
- 2026-11-10
- DOI
- https://doi.org/10.1093/jpids/piag116
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.00